AMH Tests Redraw Midlife Care
2026-10-02
A faint line in a lab readout may prove more useful than the usual hormone snapshot. Ultrasensitive anti-Mullerian hormone, or AMH, assays can detect concentrations that standard tests miss, exposing a quieter phase of ovarian decline during the crowded years between fertility planning and menopause. The signal arrives early.
It is not prophecy. AMH is secreted chiefly by granulosa cells surrounding small growing follicles, so its concentration offers an indirect estimate of the remaining follicle pool. One number cannot declare infertility or set a menopause date. Still, when clinicians compare ultrasensitive results over time with menstrual patterns and symptoms, they may spot change before conventional thresholds produce a blank result. That matters.
The real prize is timing. During folliculogenesis, an ultrasensitive AMH result works less like an ovarian battery gauge than a background-process monitor: it tracks faint output from developing follicles, not the precise instant ovarian function stops. Pair it with estradiol, follicle-stimulating hormone, bleeding history, and symptom review; then use it to frame counseling on pregnancy plans, contraception, bone health, and treatment choices. The data must stay in context. A more granular signal could turn midlife care from reactive guesswork into an adaptive model, where a small molecular trace changes the question before the body forces an answer.
Loading...
